Anti-nerve growth factor in pain management: current evidence

References

• GaskinDJRichardPThe economic costs of pain in the United StatesJ Pain201213871572422607834
   PubMed Web of Science ®Google Scholar
• KissinIThe development of new analgesics over the past 50 years: a lack of real breakthrough drugsAnesth Analg2010110378078920185657
   PubMed Web of Science ®Google Scholar
• WoolfCJMaxMBMechanism-based pain diagnosis: issues for analgesic drug developmentAnesthesiology200195124124911465563
   PubMed Web of Science ®Google Scholar
• CohenSPMaoJNeuropathic pain: mechanisms and their clinical implicationsBMJ2014348f765624500412
   PubMed Web of Science ®Google Scholar
• HsuEMurphySChangDCohenSPExpert opinion on emerging drugs: chronic low back painExpert Opin Emerg Drugs201520110312725519435
   PubMed Web of Science ®Google Scholar
• KissinIScientometrics of drug discovery efforts: pain-related molecular targetsDrug Des Devel Ther2015933933404
   PubMed Web of Science ®Google Scholar
• AloeLRita Levi-Montalcini: the discovery of nerve growth factor and modern neurobiologyTrends Cell Biol200414739539915246433
   PubMed Web of Science ®Google Scholar
• AloeLRoccoMLBianchiPManniLNerve growth factor: from the early discoveries to potential clinical useJ Transl Med20121023923190582
   PubMed Web of Science ®Google Scholar
• YuenECHoweCLLiYHoltzmanDMMobleyWCNerve growth factor and the neurotrophic factor hypothesisBrain Dev19961853623688891230
   PubMed Web of Science ®Google Scholar
• HeftiFFRosenthalAWalickePANovel class of pain drugs based on antagonism of NGFTrends Pharmacol Sci2006272859116376998
   PubMed Web of Science ®Google Scholar
• BennettDLHNeurotrophic factors: important regulators of nociceptive functionNeuroscientist200171131711486340
   PubMed Web of Science ®Google Scholar
• WatsonJJAllenSJDawbarnDTargeting nerve growth factor in pain: what is the therapeutic potential?BioDrugs200822634935918998753
   PubMed Web of Science ®Google Scholar
• McKelveyLShortenGDO’KeeffeGWNerve growth factor-mediated regulation of pain signaling and proposed new intervention strategies in clinical pain managementJ Neurochem2013124327628923157347
   PubMed Web of Science ®Google Scholar
• MantyhPWKoltzenburgMMendellLMTiveLSheltonDLAntagonism of nerve growth factor-trkA signaling and the relief of painAnesthesiology2011115118920421602663
   PubMed Web of Science ®Google Scholar
• AndreevNYDimitrievaNKolzenburgMMcMahonSBPeripheral administration of nerve growth factor in the adult rat produces a thermal hyperalgesia that requires the presence of sympathetic post-ganglionic neuronsPain19956311091158577480
   PubMed Web of Science ®Google Scholar
• DyckPJPeroutkaSRaskCIntradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humansNeurology19974825015059040746
   PubMed Web of Science ®Google Scholar
• ChuangHPrescottEDKongHBradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibitionNature2001411684095796211418861
   PubMed Web of Science ®Google Scholar
• JiRRSamadTAJinSXSchmollRWoolfCJP38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesiaNeuron2002361576812367506
   PubMed Web of Science ®Google Scholar
• SteinATUfret-VincentyCAHuaLSantanaLFGordonSEPhosphoinositide 3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the plasma membraneJ Gen Physiol2006128550952217074976
   PubMed Web of Science ®Google Scholar
• UgoliniGMarinelliSCovaceuszachSCattaneoAPavoneFThe function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic painProc Natl Acad Sci U S A200710482985299017301229
   PubMed Web of Science ®Google Scholar
• WildKDBianDZhuDAntibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without toleranceJ Pharmacol Exp Ther2007322128228717431136
   PubMed Web of Science ®Google Scholar
• GoldBGMobleyWCMathesonSFRegulation of axonal caliber, neurofilament content, and nuclear localization in mature sensory neurons by nerve growth factorJ Neurosci19911149439452010817
   PubMed Web of Science ®Google Scholar
• ApfelSCKesslerJAAdomatoBTLitchyWJSandersCRaskCARecombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF study groupNeurology1998516957029748012
   PubMed Web of Science ®Google Scholar
• ApfelSCSchwartzSAdomatoBTFreemanRBitonVEfficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF clinical investigative groupJAMA20002842215222111056593
   PubMed Web of Science ®Google Scholar
• McArthurJCYiannoutsosCSimpsonDMA phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291Neurology20005451080108810720278
   PubMed Web of Science ®Google Scholar
• SchifittoGYiannoutsosCSimpsonDMLong-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathyNeurology20015771313131611591856
   PubMed Web of Science ®Google Scholar
• MantyhWGJimenez-AndradeJMStakeJIBlockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer painNeuroscience2010171258859820851743
   PubMed Web of Science ®Google Scholar
• WoolfCJSafieh-GarabedianBMaQPCrillyPWinterJNerve growth factor contributes to the generation of inflammatory sensory hypersensitivityNeuroscience19946223273317530342
   PubMed Web of Science ®Google Scholar
• LambKKangYMGebhartGFBielefeldtKNerve growth factor and gastric hyperalgesia in the ratNeurogastroenterol Motil200315435536112846723
   PubMed Web of Science ®Google Scholar
• GueriosSDWangZYBoldonKBushmanWBjorlingDEBlockade of NGF and trk receptors inhibits increased peripheral mechanical sensitivity accompanying cystitis in ratsAm J Physiol Regul Integr Comp Physiol20082951R111R12218448607
   PubMed Web of Science ®Google Scholar
• DelafoyLRaymondFDohertyAMEschalierADiopLRole of nerve growth factor in the trinitrobenzene sulfonic acid-induced colonic hypersensitivityPain2003105348949714527709
   PubMed Web of Science ®Google Scholar
• SheltonDLZellerJHoWHPonsJRosenthalANerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritisPain20051161–281615927377
   PubMed Web of Science ®Google Scholar
• SevcikMAGhilardiJRPetersCMAnti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitizationPain20051151–212814115836976
   PubMed Web of Science ®Google Scholar
• Jiminez-AndradeJMMartinCDKoewlerNJNerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracturePain20071331–318319617693023
   PubMed Web of Science ®Google Scholar
• KoewlerNJFreemanKTBuusRJEffects of monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femurJ Bone Miner Res200722111732174217638576
   PubMed Web of Science ®Google Scholar
• SchnitzerTJMarksJAA systematic review of the efficacy and general safety of antibodies to NGF in the treatment of OA of the hip or kneeOsteoarthritis Cartilage201523Suppl 1S8S1725527221
   PubMed Web of Science ®Google Scholar
• LaneNEWebsterLShiao-pingLGrayMHeftiFWalickePRN624 (anti-NGF) improves pain and function in subjects with moderate knee osteoarthritis: a phase I studyArthritis Rheum200552S461
   PubMed Web of Science ®Google Scholar
• HeftiFMokhtaraniMGrayMZhaoCChanCRN624 (anti-NGF) reduces pain and improves function in subjects with moderate to severe pain from osteoarthritis of the kneeJ Pain200674S45
   Google Scholar
• LaneNESchnitzerTJBirbaraCATanezumab for the treatment of pain from osteoarthritis of the kneeN Engl J Med20103631521153120942668
   PubMed Web of Science ®Google Scholar
• SchnitzerTJLaneNEBirbaraCSmithMDSimpsonSLBrownMTLong-term open-label study of tanezumab for moderate to severe osteoarthritic knee painOsteoarthritis Cartilage201119663964621251985
   PubMed Web of Science ®Google Scholar
• BrownMTMurphyFTRadinDMDavignonISmithMDWestCRTanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trialJ Pain201213879079822784777
   PubMed Web of Science ®Google Scholar
• BrownMTMurphyFTRadinDMDavignonISmithMDWestCRTanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trialArthritis Rheum20136571795180323553790
   PubMed Web of Science ®Google Scholar
• SpieringsELFidelholtzJWolframGSmithMDBrownMTWestCRA phase III placebo- and oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or kneePain201315491603161223707270
   PubMed Web of Science ®Google Scholar
• EkmanEFGimbelJSBelloAEEfficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxenJ Rheumatol201441112249225925274899
   PubMed Web of Science ®Google Scholar
• SangaPKatzNPolverejanEEfficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis painPain2013154101910191923748114
   PubMed Web of Science ®Google Scholar
• TiseoPJKivitzAJErvinJEFasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double blind, placebo-controlled exploratory study in osteoarthritis of the kneePain201415571245125224686255
   PubMed Web of Science ®Google Scholar
• BalanescuARFeistEWolframGEfficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trialAnn Rheum Dis20147391665167223852695
   PubMed Web of Science ®Google Scholar
• MayorgaAWangSWangSKelleyKThipphawongJDouble-blind, randomized study to evaluate efficacy, and safety of fulranumab in patients with moderate to severe, chronic knee pain from osteoarthritis: interim analysis resultsJ Pain2013144S69
   Web of Science ®Google Scholar
• NagashimaHSuzukiMArakiSYamabeTMutoCPreliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebocontrolled studyOsteoarthritis Cartilage201119121405141222004765
   PubMed Web of Science ®Google Scholar
• SchnitzerTJEkmanEFSpieringsELEfficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treatment of knee or hip osteoarthritis painAnn Rheum Dis20157461202121124625625
   PubMed Web of Science ®Google Scholar
• KatzNBorensteinDGBirbaraCEfficacy and safety of tanezumab in the treatment of chronic low back painPain2011152102248225821696889
   PubMed Web of Science ®Google Scholar
• KivitzAJGimbelJSBramsonCEfficacy and safety of tanezumab versus naproxen in the treatment of chronic low back painPain201315471009102123628600
   PubMed Web of Science ®Google Scholar
• GimbelJSKivitzAJBramsonCLong-term safety and effectiveness of tanezumab as treatment for chronic low back painPain201415591793180124937440
   PubMed Web of Science ®Google Scholar
• SangaPKarcherKWangSEfficacy, safety, and tolerability of fulranumab in treatment of patients with moderate-to-severe, chronic low back pain [abstract]J Pain201112Suppl453
   Google Scholar
• TiseoPJRenHMellisSFasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept studyJ Pain Res2014752353025210473
   PubMed Web of Science ®Google Scholar
• BramsonCHermannDNCareyWExploring the role of tanezumab as a novel treatment for the relief of neuropathic painPain Med20151661163117625594611
   PubMed Web of Science ®Google Scholar
• WangHRomanoGFrutasciMEFulranumab for treatment of diabetic peripheral neuropathic pain: A randomized controlled trialNeurology20148362863725008392
   PubMed Web of Science ®Google Scholar
• EvansRJMoldwinRMCossonsNDarekarAMillsIWScholfieldDProof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitisJ Urol201118551716172121420111
   PubMed Web of Science ®Google Scholar
• NickelJCAtkinsonGKriegerJNPreliminary assessment of safety and efficacy in proof-of-concept, randomized clinical trial of tanezumab for chronic prostatitis/chronic pelvic pain syndromeUrology20128051105111023010344
   PubMed Web of Science ®Google Scholar
• SopataMKatzNCareyWEfficacy and safety of tanezumab in the treatment of pain from bone metastasesPain201515691703171325919474
   PubMed Web of Science ®Google Scholar
• BannwarthBKostineMTargeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?Drugs201474661962624691709
   PubMed Web of Science ®Google Scholar
• HochbergMCSerious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodiesOsteoarthritis Cartilage201523Suppl 1S18S2125527216
   PubMed Web of Science ®Google Scholar
• Janssen Research & Development LLC [webpage on the Internet]Advisory Committee Briefing Document, JNJ-42160443 (Fulranumab)2012 Available from: http://www.fda.gov/downloads/Advisory-Committees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisory-Committee/UCM295204.pdfAccessed November 14, 2015
   Google Scholar
• Food and Drug Administration Center for Drug Evaluation and Research [webpage on the Internet]Arthritis Advisory Committee Meeting2012 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisory-Committee/UCM301302.pdfAccessed November 14, 2015
   Google Scholar
• Food and Drug Administration Center for Drug Evaluation and Research [webpage on the Internet]Summary Minutes of the Arthritis Advisory Committee Meeting2012 Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM307879.pdfAccessed November 14, 2015
   Google Scholar
• RoemerFWHayesCWMillerCGImaging atlas for eligibility and on-study safety of potential knee adverse events in anti0NGF studies (Part 1)Osteoarthritis Cartilage201523Suppl 1S22S4225527217
   PubMed Web of Science ®Google Scholar
• Pfizer [webpage on the Internet]Long Term Safety and Efficacy Study of Tanezumab in Subjects with Osteoarthritis of the Hip or Knee Available from: https://clinicaltrials.gov/ct2/show/NCT02528188Accessed November 14, 2015
   Google Scholar
• Pfizer [webpage on the Internet]A Phase 3 Study of Tanezumab for Chronic Low Back Pain (TANGO) Available from: https://clinicaltrials.gov/ct2/show/NCT02528253Accessed November 14, 2015
   Google Scholar
• Janssen Research & Development LLC [webpage on the Internet]Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003 Available from: https://clinicaltrials.gov/ct2/show/NCT02289716Accessed November 14, 2015
   Google Scholar
• Janssen Research & Development LLC [webpage on the Internet]Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002 Available from: https://clinicaltrials.gov/ct2/show/NCT02336698Accessed November 14, 2015
   Google Scholar
• Janssen Research & Development LLC [webpage on the Internet]Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001 Available from: https://clinicaltrials.gov/ct2/show/NCT02336685Accessed November 14, 2015
   Google Scholar
• Janssen Research & Development LLC [webpage on the Internet]Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007 Available from: https://clinicaltrials.gov/ct2/show/NCT02301234Accessed November 14, 2015
   Google Scholar
• Regeneron Pharmaceuticals [webpage on the Internet]Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects Available from: https://clinicaltrials.gov/ct2/show/NCT02516618Accessed November 14, 2015
   Google Scholar
• OwolabiJBRizkallaGTehimACharacterization of antiiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in ratJ Pharmacol Exp Ther199928931271127610336516
   PubMed Web of Science ®Google Scholar
• WinstonJHTomaHShenoyMAcute pancreatitis results in referred mechanical hypersensitivity and neuropeptide up-regulation that can be suppressed by the protein kinase inhibitor k252aJ Pain20034632933714622690
   PubMed Web of Science ®Google Scholar
• ChenBZhaoLLiXSyntaxin 8 modulates the post-synthetic trafficking of the TrkA receptor and inflammatory pain transmissionJ Biol Chem201428928195561956924872407
   PubMed Web of Science ®Google Scholar
• BowlerKEWorsleyMABroadLThe effect of a monoclonal antibody to calcitonin-gene related peptide (CGRP) on injury-induced ectopic discharge following lingual nerve injuryNeurosci Lett2011505214614922005578
   PubMed Web of Science ®Google Scholar
• LeeJHParkCKChenGA monoclonal antibody that targets a NaV1.7 channel voltage sensor for pain and itch reliefCell201415761393140424856969
   PubMed Web of Science ®Google Scholar
• BachmannMFWhiteheadPActive immunotherapy for chronic diseaseVaccine201331141777178423415932
   PubMed Web of Science ®Google Scholar
• BachPBNew math on drug cost-effectivenessN Engl J Med2015373191797179926535510
   PubMed Web of Science ®Google Scholar